Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University of Pennsylvania
With
National Institute on Drug Abuse (NIDA)
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Ages 18 or older
Male, female, transgender, or non-binary
DSM-5 criteria for opioid use disorder, moderate to severe
Fentanyl positive on urine drug test
Able to provide written informed consent in English prior to any study-related procedure
You may not be if
Pregnancy or actively lactating
Previously documented hypersensitivity or allergy to buprenorphine or naloxone
DSM-5 criteria for substance use disorder other than opioid use disorder (e.g., cannabis, cocaine, alcohol)
Current benzodiazepine use
Urine drug testing at screening positive for buprenorphine and/or methadone
AST and/or ALT \>3x upper limit of normal or total bilirubin \>1.5x upper limit of normal
eGFR \<30 mL/min
Use of CYP3A4-metabolized agents such as azole antifungals, macrolides, and protease inhibitors
High risk of severe medetomidine withdrawal based on drug urine testing for medetomidine, prior withdrawal syndrome requiring intensive care unit admission, and/or patient-reported severe nausea/vomiting during early withdrawal, at the discretion of the study physicians.
Significant medical symptoms (e.g. severe respiratory insufficiency), psychiatric symptoms, or dementia that, in the opinion of the investigators, would preclude compliance with the protocol, cooperation in the study, obtaining informed consent, or ability to safely participate in the study
Pending legal action that could prohibit participation and/or compliance in study procedures